Analysis: Questions over AstraZeneca’s COVID-19 vaccine data risk delaying approval
Analysis: Questions over AstraZeneca’s COVID-19 vaccine data risk delaying approval
LONDON: Days after grabbing headlines with its COVID-19 vaccine for the world, AstraZeneca is facing tricky questions about its success rate that some experts say could hinder its chances of getting speedy U.S. and EU regulatory approval.
Several scientists have raised doubts about the robustness of results showing the shot was 90
